Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT06507475
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Participants treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.

Study Details

This study aims to describe the effectiveness of oral semaglutide on glycemic control and body weight control and describe characteristics of type 2 diabetes (T2D) adult patients who are being treated with oral semaglutide in Thailand. Data of eligible patients with T2D will be collected via electronic medical record or paper-format chart review to assess the effectiveness of oral semaglutide. Total study duration for the individual patient will be six months from baseline. The study duration expands within the window period will be 12 months from baseline which will be the optional visit.

Key Dates

Start date
Sep 7, 2024
Status verified
Dec 2025
Primary completion
Dec 20, 2024
Completion
Dec 20, 2024

Study Design

Enrollment
209 participants (actual)

Arms

  • Arm: Semaglutide
    Participants diagnosed with type 2 diabetes (T2D) who had initiated once-daily oral semaglutide during the target selection period of April 2022 to December 2023 and have not previously been treated with injectable glucose-lowering medication in routine clinical practice.

Primary Outcome Measure

Change in Glycated Haemoglobin (HbA1c) [ Time Frame: Baseline (week 0), end of study (week 26) ]

Related Studies